Company news
Neuren Pharmaceuticals Limited (ASX:NEU) news
Neuren Pharmaceuticals Limited news releases on 6ix. Latest, Oct 6, 2021: $3.3 million raised from oversubscribed SPP
Press releases — page 3
$3.3 million raised from oversubscribed SPP
October 5, 2021
Feedback on Angelman IND and submission of Pitt Hopkins IND
October 1, 2021
IND application submitted for NNZ-2591 in Phelan-McDermid
September 20, 2021
Share Purchase Plan Offer Booklet
September 16, 2021
Investor Presentation, 13 September 2021
September 12, 2021
FDA grants Orphan Drug designation for Prader-Willi syndrome
September 3, 2021
Angelman IND and Ethics applications submitted for NNZ-2591
August 31, 2021
R&D Tax Incentive Advance Overseas Finding Approval
August 30, 2021
Phase 3 enrolment successfully completed, results in Q4 2021
August 4, 2021
Q2 2021 quarterly activity and cash flow report
July 30, 2021
Positive FDA meetings enable INDs for three Phase 2 trials
May 31, 2021
New patent issued to 2032 for Neurens trofinetide in Canada
April 28, 2021
Quarterly report and cash flow statement for Q1 2021
April 22, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Neuren successfully completes manufacturing for Phase 2
March 9, 2021
Neuren approaching transforming milestones in 2021
February 23, 2021
Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline
February 15, 2021
Successful Phase 1 trial for Neurens NNZ-2591
February 14, 2021
Quarterly report and cash flow statement for Q4 2020
January 28, 2021
European Commission grants 3 NNZ-2591 Orphan designations
January 10, 2021
Positive opinion for all 3 Orphan applications in Europe
December 6, 2020
Approval received for final stage of NNZ-2591 clinical trial
November 18, 2020
Quarterly report and cash flow statement for Q3 2020
October 28, 2020
Neuren initiates manufacture of NNZ-2591 for Phase 2 trials
September 22, 2020
Q2 2020 Activity Report and Cash Flow Report
July 27, 2020
Proposed issue of Securities - NEU
June 28, 2020
Temporary enrolment pause ended in Phase 3 trial in the US
June 15, 2020
Neuren announces changes to leadership team
May 26, 2020
Neuren commences first clinical trial for NNZ-2591
May 7, 2020
Appendix 4C - quarterly
April 17, 2020
Q1 2020 Activity Report
April 16, 2020
First patent in Israel granted for trofinetide
April 1, 2020
Temporary pause in new enrolments for LAVENDER trial in US
March 23, 2020
Neuren to capture substantially greater value after Phase 3
March 16, 2020
Compelling results for 2591 dose ranging study in PMS model
March 5, 2020
Commentary on potential benefit to Neuren of RPD designation
March 3, 2020
Appendix 4E and 2019 full year accounts
February 25, 2020
Update on trofinetide Phase 3 trial in Rett syndrome
February 19, 2020
2019 year-end update and 2020 outlook
December 11, 2019
Patent to 2034 granted in Europe for Neurens NNZ-2591
December 2, 2019
Phase 3 trial of trofinetide in Rett syndrome commences
October 30, 2019
Neuren Pharmaceuticals : FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
October 17, 2019
FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
October 15, 2019
FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
October 11, 2019
Neuren approaching key milestones in Q4 2019
September 20, 2019
NNZ-2591 positive effects in Pitt Hopkins syndrome model
May 17, 2019
NNZ-2591 positive effects in Angelman syndrome model
May 16, 2019
Update on development plan for NNZ-2591
April 26, 2019
Neurens Rett syndrome Phase 2 trial published in Neurology
March 27, 2019
Preliminary Final Report and statutory accounts
February 27, 2019